STEINIA LEWIS: Open Payments
NPI 1295187615 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$513 in 25 payments from 10 companies in 2025. Trend: 2023 $849 · 2024 $1,179 · 2025 $513
Food & beverage: $513
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $84 |
| Neurocrine BioSciences, Inc. | 4 | $80 |
| Janssen Pharmaceuticals, Inc | 4 | $75 |
| Vanda Pharmaceuticals Inc. | 2 | $67 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Biogen, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
Products named: VRAYLAR, INGREZZA, FANAPT, Jornay PM, SPRAVATO, TRINTELLIX, ZURZUVAE, INVEGA SUSTENNA.
Industry payments across UT — which companies pay providers there.
